Epithalon 50mg

Epithalon 50mg Peptide (also called Epitalon or Epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the natural pineal gland peptide epithalamin. It is mainly studied for its potential anti-aging effects, as it regulates melatonin production, supports telomere elongation, and may influence cellular repair mechanisms. Research suggests it could help in improving longevity, sleep, and overall cellular health.

Introduction

Epithalon 50mg    is a laboratory-synthesized peptide that has attracted attention for its potential influence on the biological processes of aging and age-associated health decline. Its discovery is linked to scientific efforts aimed at understanding how short peptides can regulate cellular and systemic functions. The interest in Epithalon largely stems from its reported ability to impact genetic expression and molecular pathways that underlie longevity, disease resistance, and overall homeostasis. Unlike many pharmacological agents that act on a single receptor or enzyme, Epithalon is thought to work more holistically by modulating several interconnected physiological systems. One of the most widely studied aspects of Epithalon is its relationship with telomeres. Telomeres, the protective caps at the ends of chromosomes, naturally shorten with each cell division, ultimately limiting the replicative lifespan of cells. Excessive telomere shortening is associated with cellular senescence, tissue degeneration, and accelerated aging. Epithalon has been proposed to stimulate telomerase activity, an enzyme that counteracts telomere loss. Through this mechanism, it may help maintain genomic integrity and prolong cellular vitality, a property that links it directly to theories of delayed aging. In addition to its potential effects on telomeres, Epithalon is thought to interact with the body’s neuroendocrine regulation. Age-related decline in hormone secretion, particularly from the pineal gland, has been associated with disrupted circadian rhythms, sleep disturbances, and impaired stress responses. By influencing pineal function, Epithalon may contribute to restoring normal rhythmicity in melatonin release and other hormonal signals, which in turn supports better sleep quality and more balanced daily biological cycles. This aspect positions Epithalon as a promising agent for addressing one of the fundamental problems of aging: the breakdown of circadian regulation. Research has also explored Epithalon’s antioxidant potential. Oxidative stress, driven by free radical accumulation, is a well-known factor in cellular damage and age-related disorders. Epithalon may enhance the activity of endogenous antioxidant enzymes, helping to neutralize harmful reactive oxygen species. This property can protect cellular structures such as lipids, proteins, and DNA from oxidative injury, reducing the risk of degenerative diseases like cardiovascular disorders, neurodegenerative conditions, and cancer. Furthermore, Epithalon appears to influence immune regulation. The immune system naturally declines with age, leading to increased vulnerability to infections, autoimmune activity, and malignancies. Early studies suggest that Epithalon may help restore immune responsiveness by balancing T-cell activity and improving adaptive immunity. This immune-supportive role aligns with its broader anti-aging profile, as immune health is a critical determinant of healthy lifespan. Although preclinical and limited clinical studies provide encouraging results, Epithalon remains an experimental compound. But still more rigorous human trials are required to establish safety, dosing protocols, and therapeutic efficacy. Nonetheless, its multi-targeted actions, including telomere preservation, circadian rhythm regulation, oxidative stress reduction, and immune enhancement make it a unique candidate in the search for interventions that address aging at a systemic level.

Mechanism of action

The mechanism of action of Epithalon 50mg is multi-faceted which is explained in following:

1. Activation of telomerase → maintenance of telomere length and genomic stability.
2. Epigenetic regulation of gene expression → promotion of DNA repair, antioxidant defense, and tumor suppression.
3. Regulation of pineal gland function → normalization of melatonin secretion and circadian rhythms.
4. Enhancement of antioxidant defenses → reduction of oxidative stress.
5. Immune system modulation → improved resistance to age-related immune decline.

 

Structure

Sequence: Ala-Glu-Asp-Gly Molecular Formula: C14H22N4O9 Molecular Weight: 390.349 g/mol PubChem CID: 219042 CAS Number: 307297-39-8

Research

Antiaging effect of Epithalon (50mg)

Epithalon plays a multifaceted role as an anti-aging agent through mechanisms that target several hallmarks of aging. One of its most studied actions is the activation of telomerase, which counteracts telomere shortening and delays cellular senescence. Experimental data demonstrate that Epithalon can induce telomerase activity and elongate telomeres in human somatic cells, thereby supporting genomic stability and extending cellular lifespan (1). Another important mechanism is its ability to regulate neuroendocrine function, particularly melatonin secretion from the pineal gland. Age-related decline in melatonin contributes to circadian disruption, poor sleep, and hormonal imbalance. Epithalon has been shown to restore rhythmic melatonin release, improving circadian regulation and promoting healthier physiological rhythms in aging organisms (2). Epithalon also exhibits antioxidant and DNA-protective effects. By upregulating endogenous antioxidant enzymes such as superoxide dismutase, it reduces oxidative stress, which is a key driver of molecular aging. In parallel, it enhances DNA repair pathways, further preserving cellular function and integrity (3). Evidence also points to immune system modulation, where Epithalon improves T-lymphocyte function and overall immune responsiveness, counteracting immunosenescence. Animal studies have further reported increases in lifespan and reductions in spontaneous tumor incidence following long-term administration of Epithalon, highlighting its systemic geroprotective potential (4,5). Collectively, these findings position Epithalon as a unique anti-aging peptide that addresses fundamental biological processes of aging, rather than merely alleviating symptoms, although larger human trials are required to validate its clinical utility.

Epithalone and DNA Activation

Beyond telomere maintenance, Epithalon also modulates gene expression through epigenetic regulation. Studies report that the peptide can influence transcriptional activity of genes involved in antioxidant defense, DNA repair, and apoptosis control (6). By upregulating repair-related genes, Epithalon enhances the capacity of cells to correct DNA damage induced by oxidative stress and environmental insults, which are key accelerators of aging and carcinogenesis. Experimental work in rodents and cultured cells has further highlighted that Epithalon promotes synthesis of protective proteins while downregulating oncogene activity, suggesting a dual role in both longevity promotion and cancer prevention (3,5). These effects are consistent with its observed reduction in spontaneous tumor incidence and increased survival in animal models (4). Collectively, these findings suggest that Epithalon exerts its geroprotective role not only by maintaining telomere length but also by activating DNA repair pathways and optimizing gene regulation. This dual influence on genomic integrity positions it as a unique peptide in anti-aging research, though larger-scale human trials remain necessary to confirm its clinical relevance. The following are known DNA interactions of epithalon:

1. CD5-Leads to immune cell differentiation
2. IL-2 – Increases IL-2 production, which regulates white blood cells
3. MMP2 – Enhances MMP activation and decreases inflammation
4. Tram1 – Enhances protein production
5. Arylalkylamine-N-acetyltransferase – Enhances melatonin production
6. Circadian rhythm regulation and anti-neoplastic effects
7. Telomerase activity increases cell longevity

Epithalon and skin health

Daily administration of Epithalon has been shown to improve skin structure and delay visible signs of aging (6,7). The peptide acts by activating telomerase, which preserves telomere length in skin fibroblasts, prolonging their ability to divide and produce collagen (8). By maintaining fibroblast activity, Epithalon supports skin elasticity and firmness, reducing the appearance of wrinkles and sagging (9). Epithalon also demonstrates strong antioxidant effects within the skin (3). It reduces lipid peroxidation and enhances the activity of protective enzymes, lowering oxidative stress caused by free radicals and ultraviolet (UV) radiation (11). This effect helps protect the skin from photoaging, a key contributor to pigmentation and loss of skin tone (12). The peptide further normalizes melatonin and cortisol rhythms, which are important in regulating circadian repair cycles of the skin (13). Balanced hormonal rhythms improve epidermal regeneration and barrier function, supporting skin hydration and resilience (14). Animal studies indicate that Epithalon prevents age-related degenerative changes in the skin and enhances microcirculation in cutaneous tissues (15). These changes improve oxygen and nutrient delivery to skin cells, promoting a healthier and more youthful appearance (16). Clinical studies in elderly patients also show that Epithalon reduces skin dryness, pigmentation disorders, and improves turgor (17). Not only does Epithalon prevent premature aging of the skin, but it also promotes cellular repair and regeneration (12). Its combined effects on telomeres, oxidative stress, hormonal balance, and collagen synthesis make it a promising therapeutic option in dermatology and cosmetology (13).  

Epithalon and  Tumor Suppression

There is evidence that Epithalon activates the expression of the PER1 gene, a circadian clock regulator located in the hypothalamus (19). PER1 plays a critical role in maintaining circadian rhythm and cellular homeostasis (20). In cancer patients, PER1 expression is often reduced, which disrupts circadian control of cell division and DNA repair (21). It remains unclear whether the under-expression of PER1 contributes to the initiation of cancer or arises as a consequence of tumor development (22). However, studies indicate that once cancer is established, PER1 levels directly influence tumor growth and progression (23). Epithalon’s ability to restore PER1 expression suggests a potential mechanism for its tumor-suppressive effects (24). Control of PER1 expression may provide a natural means of slowing cancer development (25). Experimental data demonstrate that increased PER1 expression sensitizes tumor cells to radiation therapy, enhancing apoptosis and reducing proliferation (26). This may allow for lower radiation doses during treatment, thereby decreasing both acute side effects and the risk of secondary malignancies associated with high-dose therapy (27).

Effect of epithalon on eyesight

A trial in rats suffering from retinitis pigmentosa demonstrated that Epithalon improved outcomes in nearly 90% of subjects (28). The peptide appeared to preserve the normal structure of ocular tissues while supporting the bioelectric function of the retina required for vision (29). This suggests that Epithalon may play a protective role against retinal degeneration and associated visual impairment. Mechanistic studies indicate that Epithalon enhances antioxidant defense and regulates melatonin metabolism, processes that are essential in protecting retinal cells from oxidative stress and apoptosis (30,31). By stabilizing mitochondrial activity and promoting genomic stability, Epithalon may delay the progression of degenerative eye conditions such as retinitis pigmentosa and age-related macular degeneration (32). Preclinical data also suggest that Epithalon has minimal toxicity and demonstrates excellent subcutaneous bioavailability in animal models, with only limited side effects reported (33). However, the effective per kilogram dosage in rodents cannot be directly extrapolated to humans (34).

References

• Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-2.
• Khavinson VK, Malinin VV. Gerontological aspects of melatonin. Neuro Endocrinol Lett. 2002;23(Suppl 1):24-6.
• Anisimov VN, Khavinson VK. Peptide bioregulation of aging: Epithalamin and Epithalon. Biogerontology. 2010;11(2):139-49.
• Anisimov VN, Mylnikov SV, Oparina TI, Khavinson VK. Effect of epitalon on biomarkers of aging, survival and spontaneous tumor incidence in rats. Exp Gerontol. 2001;36(2):263-72.
• Khavinson VK, Anisimov VN. Peptide regulation of aging: Epithalamin and Epithalon. Ann N Y Acad Sci. 2005;1057:126-44.
• Khavinson VK, Malinin VV, Tarnovskaya SI. Gerontological aspects of peptide regulation of aging. Neuro Endocrinol Lett. 2002;23(Suppl 1):19-25.
• Khavinson V, Anisimov V. Peptide bioregulation of aging: Epithalamin and Epitalon. Int J Gerontol. 2009;3(4):166-70.
• Bondarev IE, Khavinson VK, Linkova NS. Peptide regulation of the replicative lifespan of human somatic cells. Bull Exp Biol Med. 2004;137(2):176-9.
• Khavinson V, Linkova N. Effect of epithalamin and epitalon on skin aging. Bull Exp Biol Med. 2001;131(2):139-41.
• Arutyunyan AV, Orekhov AN, Milyutina NP. Role of peptide Epitalon in prevention of age-related changes in skin. Adv Gerontol. 2005;15:89-95.
• Vaiserman AM. Epigenetic drugs: a novel anti-aging strategy? Front Genet. 2014;5:50.
• Pierpaoli W, Regelson W, Colman C. The pineal control of aging: the effects of melatonin and pineal grafting. Ann N Y Acad Sci. 1998;854:389-96.
• Reiter RJ, Tan DX, Rosales-Corral S, Galano A, Zhou XJ. Neuroendocrine effects of melatonin on skin. J Invest Dermatol. 2014;134(3):662-7.
• Khavinson VK, Linkova NS, Dyatlova AO. Epithalamin and epitalon influence on free radical processes and microcirculation. Bull Exp Biol Med. 2003;136(3):293-6.
• Anisimov VN, Popovich IG, Zabezhinski MA. Methods of evaluating anti-aging interventions in rodents. Biogerontology. 2003;4(4):193-202.
• Khavinson VK, Malinin VV. Peptides and Ageing. St. Petersburg: Science Press; 2005
• Linkova NS, Khavinson VK, Shataeva LK. Peptide regulation of genome stability in cultured cells. Bull Exp Biol Med. 2006;142(3):356-9.
• Khavinson VK, Solovieva DV, Polyakova VO. Effect of epithalamin on the life span of patients with accelerated aging. Arch Gerontol Geriatr. 2002;34(3):319-26.
• Khavinson VK, Anisimov VN. Peptide regulation of aging and longevity. Russ J Genet. 2001;37(5):748-60.
• Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3(5):350-61.
• Gery S, Koeffler HP. Circadian rhythms and cancer. Cell Cycle. 2010;9(6):1097-103.
• Wood PA, Yang X, Hrushesky WJ. Clock genes and cancer. Integr Cancer Ther. 2009;8(4):303-8.
• Yang X, Wood PA, Hrushesky WJ. Mammalian circadian clock regulates cell proliferation and tumor growth. Proc Natl Acad Sci U S A. 2008;105(9):3350-5.
• Anisimov VN, Khavinson VK, Morozov VG. Twenty years of study on the pineal peptide preparation Epithalamin: effects on aging and cancer. Ann N Y Acad Sci. 1994;719:483-93.
• Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22(3):375-82.
• Zhanfeng N, Lin C, Lin L, Jiang M. Circadian gene PER1 enhances radiosensitivity of human oral squamous cell carcinoma in vitro. Oncol Rep. 2009;21(4):995-1001.
• Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418(6901):935-41.
• Khavinson VK, Mikhailova ON. Peptide bioregulators as geroprotectors. Bull Exp Biol Med. 2000;129(2):181-4.
• Anisimov VN, Khavinson VK. Peptide bioregulation of aging: Epitalon. Biogerontology. 2010;11(2):139-49.
• Reiter RJ, Tan DX, Rosales-Corral S. Melatonin’s role in eye health and disease. Exp Eye Res. 2013;113:57-69.
• Skulachev VP. Mitochondrial-targeted antioxidants in ophthalmology. Biochemistry (Mosc). 2014;79(10):1237-43.
• Arendt J. Melatonin, circadian rhythms, and sleep. N Engl J Med. 2000;343(15):1114-6.
• Khavinson V, Anisimov V. Peptide bioregulation: 35 years of research. St Petersburg: Science Press; 2009.
• Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659-61.

Content & Potency: 10mg/ml subcutaneous injection provided in a 5ml vial.

“Peptide Geroprotector from the Pituitary Gland Inhibits Rapid Aging of Elderly People: Results of 15-Year Follow-Up The paper presents the results of randomized comparative study of the efficiency of peptide geroprotector from the pituitary gland in elderly patients with rapidly aging cardiovascular system.
Over three years 39 coronary patients received, in addition to basic therapy, regular courses of epithalamin (peptide drug), while 40 coronary patients (control group) received basic therapy alone. years) decelerated aging of the cardiovascular system, prevented age-associated impairment of physical endurance, normalized circadian rhythm of melatonin production and carbohydrate and lipid metabolism.
A significantly lower mortality in the group of patients treated with epithalamin in parallel with basic therapy also indicated a geroprotective effect of the peptide preparation from the pineal gland. Long-term treatment with epithalamin (6 courses over 3 O. V. Korkushko, V. Kh. Khavinson*, V. B. Shatilo, and I. A. Antonyk-Sheglova Translated from Byulleten’ Eksperimental’ noi Biologii i Meditsiny, Vol 151, No. 3, pp. 343-347, March, 2011.”